Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, together with its subsidiaries, focuses on developing and marketing pharmaceutical products in urology and sexual health worldwide. The company markets Testim for the topical treatment of hypogonadism; TESTOPEL, an implantable TRT product; Edex, a non-oral drug for erectile dysfunction (ED); Osbon ErecAid, a device for treating ED; Striant, a buccal delivery system for testosterone replacement therapy; and XIAFLEX for the treatment of adult Dupuytren's contracture patients with a palpable cord. It also markets Theo-24 for the treatment of COPD and asthma; and Semprex-D for the treatment of seasonal allergic rhinitis. In addition, the company is developing XIAFLEX, which is in Phase III clinical trial for the treatment of Peyronie's disease; and in Phase II clinical trial for the treatment of adhesive capsulitis, as well as in Phase II clinical trial for the treatment of edematous fibrosclerotic panniculopathy. Further, it is developing a high concentration testosterone gel product. The company sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors, and chain drug stores. It has collaboration with the Swedish Orphan Biovitrum AB for the development, supply, and commercialization of XIAPEX.
The company was founded in 1999 and is headquartered in Chesterbrook, Pennsylvania.
Address
640 LEE ROAD
CHESTERBROOK, PA 19087
United States
CHESTERBROOK, PA 19087
United States
Website
http://www.auxilium.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | -26.72% | 21.74% |
| Operating margin | -18.30% | 21.62% |
| EBITD margin | - | 26.20% |
| Return on average assets | -10.47% | 27.35% |
| Return on average equity | -39.29% | 60.46% |
| Employees | 526 |
No comments:
Post a Comment